ESC 2019

1-16 of 43

Smartphone-based AF screening in the general population
Smartphone-based AF screening in the general population
ESC 2019
Smartphone-based AF screening in the general population
Biochemical urine test to measure medical adherence in hypertension
Biochemical urine test to measure medical adherence in hypertension
ESC 2019
Biochemical urine test to measure medical adherence in hypertension
Hs-troponin measured 30 min after admission to diagnose MI
Hs-troponin measured 30 min after admission to diagnose MI
ESC 2019
Hs-troponin measured 30 min after admission to diagnose MI
- Camilla Bang, MD
What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?
What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?
ESC 2019
What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?
- Prof. François Mach, MD
Betablocker use associated with reduced mortality in HFrEF patients >80 years
Betablocker use associated with reduced mortality in HFrEF patients >80 years
ESC 2019
Betablocker use associated with reduced mortality in HFrEF patients >80 years
- Gianluigi Savarese, MD
Lessons from ISAR-REACT 5 about which antiplatelet agent to choose in ACS patients
Lessons from ISAR-REACT 5 about which antiplatelet agent to choose in ACS patients
ESC 2019
Lessons from ISAR-REACT 5 about which antiplatelet agent to choose in ACS patients
- Prof. Freek Verheugt
Sex-related differences in ACS patients
Sex-related differences in ACS patients
ESC 2019
Sex-related differences in ACS patients
- Sanne Peters, PhD
NP metabolism associated with clinical outcomes in HF
NP metabolism associated with clinical outcomes in HF
ESC 2019
NP metabolism associated with clinical outcomes in HF
- Frank Gommans, MD, PhD
Heterogeneity of treatment effects from intensive lifestyle intervention on CV events in T2DM
Heterogeneity of treatment effects from intensive lifestyle intervention on CV events in T2DM
ESC 2019
Heterogeneity of treatment effects from intensive lifestyle intervention on CV events in T2DM
- Jan Westerink, MD, PhD
Estimating individual lifetime benefit and bleeding risk with NOAC addition to asprin in stable CVD
Estimating individual lifetime benefit and bleeding risk with NOAC addition to asprin in stable CVD
ESC 2019
Estimating individual lifetime benefit and bleeding risk with NOAC addition to asprin in stable CVD
- Tamar de Vries, MD
CRP levels associated with risk of cancer in stable CVD
CRP levels associated with risk of cancer in stable CVD
ESC 2019
CRP levels associated with risk of cancer in stable CVD
- Cilie van ’t Klooster, MD
What is mendelian randomization?
What is mendelian randomization?
ESC 2019
What is mendelian randomization?
- Prof. Børge Nordestgaard, MD
No improved clinical outcomes with remote ischemic conditioning in STEMI patients undergoing PCI
No improved clinical outcomes with remote ischemic conditioning in STEMI patients undergoing PCI
ESC 2019
No improved clinical outcomes with remote ischemic conditioning in STEMI patients undergoing PCI
- Prof. Hans Erik Botker
BET inhibition, an epigenetic pathway: How could BET inhibition modulate atherothrombotic risk?
BET inhibition, an epigenetic pathway: How could BET inhibition modulate atherothrombotic risk?
ESC 2019
BET inhibition, an epigenetic pathway: How could BET inhibition modulate atherothrombotic risk?
- Prof. Wouter Jukema
Challenges in targeting residual risk in diabetic patients, post ACS
Challenges in targeting residual risk in diabetic patients, post ACS
ESC 2019
Challenges in targeting residual risk in diabetic patients, post ACS
- Paul Ridker, MD
Reduced long-term CV death and MI with complete multivessel revascularization in STEMI
Reduced long-term CV death and MI with complete multivessel revascularization in STEMI
ESC 2019
Reduced long-term CV death and MI with complete multivessel revascularization in STEMI
- Prof. Shamir Mehta

1/3

1-16 of 43

Title

Share on ReachMD